Background
Methods
Cohort of preterm infants
Ethics
Definitions
Pathogens detected by KRINKO recommended colonization screening
Statistical analysis
Results
Year of discharge | 2011–2013 n = 3.920 | 2014–2018 n = 8.903 | p |
---|---|---|---|
Gestational age [weeks, mean ± SD] | 26.5 ± 1.6 | 26.5 ± 1.7 | 0.62* |
Birth weight [grams, mean ± SD] | 850 ± 253 | 852 ± 256 | 0.61* |
Male gender (%, 95 CI) | 53.8 (52.2–55.4) | 53.5 (52.5–54.5) | 0.58 |
Multiple birth (%, 95 CI) | 29.1 (27.7–30.5) | 31.9 (30.9–32.9) | 0.002 |
Small for gestational age(%, 95 CI) | 14 (13.0–15.1) | 13.5 (12.8–14.2) | 0.8 |
Sepsis related mortality after introduction of colonization screening
Year of discharge | 2011–2013 n = 3.920 (%, 95 CI) | 2014–2018 n = 8.903 (%, 95 CI) | p# |
---|---|---|---|
Sepsis with positive blood culture | 16.5 (15.3–17.6) | 14.4 (13.7–15.1) | 0.003 |
Clinical sepsisa | 42.8 (41.1–44.6) | 31.4 (30.4–32.4) | < 0.001 |
Early-onset sepsisa with positive blood culture | 1.7 (1.3–2.2) | 1.4 (1.2–1.8) | 0.3 |
Late-onset sepsisa with positive blood culture | 17.0 (15.7–18.4) | 14.9 (14.0–15.8) % | 0.008 |
Gram positive sepsis | 13.2 (12.2–14.3) | 11.2 (10.6–11.9) % | 0.001 |
Gram negative sepsis | 3.8 (3.2–4.4) | 3.4 (3.0–3.8) % | 0.26 |
KRINKO I/MDRO sepsis | 0.5 (0.3–0.7) | 0.6 (0.5–0.8) % | 0.36 |
KRINKO II sepsis | 2.0 (1.6–2.5) | 2.2 (1.9–2.6) % | 0.49 |
KRINKO III sepsis | 1.1 (0.8–1.5) | 1.1 (0.9–1.3) % | 0.98 |
Candida sepsis | 0.5 (0.3–0.7) | 0.4 (0.3–0.6) % | 0.52 |
Sepsis related mortality | 2.3 (1.8–2.8) | 2.1 (1.8–2.4) % | 0.54 |
Total mortality (%, 95 CI) | 13.8 (12.8–14.9) | 12.5 (11.8–13.2) % | 0.036 |
Year of discharge | 2011 N = 1.160% | 2012 N = 1.409% | 2013 N = 1.351% | 2014 N = 1.632% | 2015 N = 1.825% | 2016 N = 1.710% | 2017 N = 1.855% | 2018 N = 1.881% |
---|---|---|---|---|---|---|---|---|
Sepsis with positive blood culture | 17.8 | 15.4 | 16.4 | 14.6 | 14.9 | 13.8 | 14.8 | 13.8 |
Clinical sepsisa | 47.5 | 41.3 | 40.7 | 37.6 | 38.2 | 28.9 | 28.5 | 27.0 |
Early-onset sepsisa with positive blood culture | 1.7 | 1.4 | 2.1 | 1.5 | 1.7 | 1.1 | 1.7 | 1.2 |
Late-onset sepsis with positive blood culturea | 18.6 | 16.5 | 16.3 | 15.5 | 15.8 | 13.9 | 15.3 | 13.8 |
Gram positive sepsis | 14.2 | 12.4 | 13.2 | 11.0 | 12.1 | 10.3 | 11.8 | 11.0 |
Gram negative sepsis | 4.6 | 3.5 | 3.4 | 3.8 | 3.2 | 3.7 | 3.2 | 3.2 |
KRINKO I/MDRO sepsis | 0.3 | 0.5 | 0.6 | 1.0 | 0.4 | 0.6 | 0.4 | 0.7 |
KRINKO II sepsis | 2.4 | 1.9 | 1.9 | 2.9 | 2.3 | 2.2 | 2.0 | 1.9 |
KRINKO III sepsis | 1.4 | 1.2 | 0.7 | 1.0 | 1.2 | 1.3 | 1.0 | 1.0 |
Candida sepsis | 0.3 | 0.6 | 0.5 | 0.8 | 0.4 | 0.6 | 0.2 | 0.2 |
Sepsis related mortality | 2.8 | 1.9 | 2.2 | 2.6 | 1.9 | 2.3 | 1.8 | 2.0 |
Total mortality | 16.0 | 12.8 | 13.0 | 12.6 | 12.1 | 12.7 | 12.0 | 13.1 |
Exposure to antibiotics
Year of discharge | 2011–2013 n = 2.948% | 2014–2018 n = 6.630% | P# |
---|---|---|---|
Any antibiotics | 96.7 | 93.3 | < 0.001 |
Penicillins | 76.6 | 66.6 | < 0.001 |
Ampicillin | 71.0 | 66.3 | < 0.001 |
Piperacillin | 15.6 | 17.5 | 0.02 |
Piperacillin/Tazobactam | 11.5 | 12.0 | 0.65 |
Aminoglycosides | 75.3 | 74.1 | 0.2 |
Gentamycin | 56.0 | 56.9 | 0.44 |
Tobramycin | 20.6 | 18.3 | 0.01 |
Glycopeptides | 53.4 | 49.2 | < 0.001 |
Vancomycin | 42.0 | 41.0 | 0.34 |
Teicoplanin | 11.8 | 9.5 | 0.001 |
Carbapenems | 33.4 | 35.4 | 0.06 |
Meropenem | 26.3 | 31.6 | < 0.001 |
Imipenem | 9.1 | 4.9 | < 0.001 |
Others | |||
Cefotaxim | 40.1 | 31.1 | < 0.001 |
Metronidazol | 6.4 | 5.4 | 0.05 |
Erythromycin | 11.8 | 9.3 | 0.001 |
Fluconazol | 4.4 | 9.5 | < 0.001 |
Amphothericin B | 1.7 | 3.5 | < 0.001 |
Pathogen-specific case fatality rate
Exposure | N exposed | Mortality due to sepsis [%] | Odds ratio* (95% CI) | p* |
---|---|---|---|---|
Gestational age [OR per additional week] | 12.823 | 2.2 | 0.7 (0.66–0.75) | < 0.001 |
Discharge 2014–2018 | 8.903 | 2.1 | 0.9 (0.73–1.23) | 0.69 |
Female sex | 5.950 | 1.8 | 0.7 (0.58–0.95) | 0.02 |
Multiple birth | 3.979 | 2.0 | 0.9 (0.70–1.22) | 0.59 |
SGA | 1.753 | 4.1 | 2.0 (1.49–2.58) | < 0.001 |
All blood cultures negative* | 10.893 | 1.5 | Ref. | |
Staph. epidermidis | 745 | 2.4 | 1.2 (0.7–2.0) | 0.74 |
Staph. haemolyticus | 196 | 5.1 | 2.6 (1.3–5.0) | 0.005 |
E coli | 169 | 11.2 | 7.3 (4.3–12) | < 0.001 |
Staph. aureus | 150 | 4.0 | 2.3 (1.00–5.3) | 0.053 |
Staph. capitis | 105 | 0 | – | |
Enterococci, no VRE | 97 | 8.2 | 4.2 (2.0–9.0) | < 0.001 |
Enterobacter spp. | 94 | 6.4 | 3.4 (1.4–7.9) | 0.005 |
Group B Strep. | 86 | 9.3 | 5.5 (2.6–12) | < 0.001 |
Klebsiella, no MDRO | 75 | 10.7 | 5.6 (2.6–12) | < 0.001 |
Candida spp | 45 | 26.7 | 16 (7.9–32) | < 0.001 |
E. coli ESBL | 32 | 12.5 | 6.7 (2.3–20) | 0.001 |
Staph. hominis | 28 | 7.1 | 4.0 (0.9–17) | 0.06 |
Enterococci, VRE | 20 | 5.0 | 2.8 (0.4–21) | 0.33 |
Serratia | 17 | 5.9 | 2.9 (0.4–23) | 0.30 |
Klebsiella ESBL | 16 | 0 | – | |
MRSA | 16 | 6.3 | 3.7 (0.5–28) | 0.21 |
Pseudomonas | 14 | 57.1 | 59 (19–180) | < 0.001 |
Other streptococci | 12 | 0 | – | |
Listeria | 8 | 12.5 | 11 (1.3–92) | 0.04 |
Pneumococci | 3 | 0 | – | |
Proteus | 1 | 0 | – | |
Bacteroides | 1 | 0 | – |